TY - JOUR
T1 - T cell coinhibition in prostate cancer
T2 - New immune evasion pathways and emerging therapeutics
AU - Barach, Yael S.
AU - Lee, Jun Sik
AU - Zang, Xingxing
N1 - Funding Information:
Y.S.B is supported by a National Institutes of Health (NIH) training grant T32GM007491. X.Z. is supported in part by NIH Type 1 Diabetes Pathfinder Award DP2DK083076 and Department of Defense Prostate Cancer Research Program New Investigator Award PC094137.
PY - 2011/1
Y1 - 2011/1
N2 - T cell-mediated adaptive immune response is controlled by both positive costimulation and negative coinhibition, generated mainly by the interaction between the B7 family and their receptor CD28 family. Coinhibition is exploited by prostate cancer as an immune evasion pathway. Overexpression of coinhibitory B7x and B7-H3 in prostate cancer correlates with poor disease outcome, whereas tumor-infiltrating immune cells have enhanced expression of PD-L1 and its receptor PD-1. New insights into the complex mechanisms governing B7 expression in the tumor microenvironment have been reported and therapies aimed at overcoming T cell coinhibition with antagonistic monoclonal antibodies are emerging as effective tumor immunotherapies. Therapies that block B7x and B7-H3, either as monotherapies or in synergism with traditional therapies, should be pursued.
AB - T cell-mediated adaptive immune response is controlled by both positive costimulation and negative coinhibition, generated mainly by the interaction between the B7 family and their receptor CD28 family. Coinhibition is exploited by prostate cancer as an immune evasion pathway. Overexpression of coinhibitory B7x and B7-H3 in prostate cancer correlates with poor disease outcome, whereas tumor-infiltrating immune cells have enhanced expression of PD-L1 and its receptor PD-1. New insights into the complex mechanisms governing B7 expression in the tumor microenvironment have been reported and therapies aimed at overcoming T cell coinhibition with antagonistic monoclonal antibodies are emerging as effective tumor immunotherapies. Therapies that block B7x and B7-H3, either as monotherapies or in synergism with traditional therapies, should be pursued.
UR - http://www.scopus.com/inward/record.url?scp=78650997385&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78650997385&partnerID=8YFLogxK
U2 - 10.1016/j.molmed.2010.09.006
DO - 10.1016/j.molmed.2010.09.006
M3 - Review article
C2 - 20971039
AN - SCOPUS:78650997385
SN - 1471-4914
VL - 17
SP - 47
EP - 55
JO - Trends in Molecular Medicine
JF - Trends in Molecular Medicine
IS - 1
ER -